Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I study

被引：1
|
作者：
Simonelli, M. [1 ]
Lorusso, D. [2 ]
Homicsko, K. [3 ,4 ]
Seguy, F. [5 ]
Kinder, M. [6 ]
Liu, Q. [7 ]
Croft, E. [8 ]
Kitano, S. [9 ]
机构：
[1] IRCCS Humanitas Res Hosp, Med Oncol, Rozzano, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS Rome & H, Gynaecol Oncol Unit, Milan, Italy
[3] UNIL, Ludiwg Inst Canc Res, Oncol Dept, Lausanne, Switzerland
[4] CHU Vaudois, Lausanne, Switzerland
[5] Incyte Biosci Int Sarl, Clin Dev, Morges, Switzerland
[6] Incyte Corp, Translat Sci, Wilmington, DE USA
[7] Incyte Corp, Biostats, Wilmington, DE USA
[8] Incyte Corp, Early Clin Dev, Wilmington, DE USA
[9] Canc Inst Hosp JFCR, Dept Adv Med Dev, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.684
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
617MO
引用
收藏
页码：S495 / S495
页数：1
相关论文
共 50 条
  • [21] Phase I study of roniciclib (BAY1000394), an oral CDK inhibitor in Japanese patients with advanced solid tumors
    Seto, Takashi
    Nosaki, Kaname
    Shinoda, Gen
    Hashizume, Kensei
    Yamaguchi, Iku
    Tsuburaya, Jun
    Nogai, Hendrik
    Shitara, Kohei
    Yoh, Kiyotaka
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors
    Aurora Norman
    Mahesh Seetharam
    Jacob Allred
    Jianping Kong
    Mateusz Opyrchal
    Wen Wee Ma
    Yanyan Lou
    Grace K. Dy
    Amit Mahipal
    S. John Weroha
    Andrea E. Wahner Hendrickson
    Joel M. Reid
    Alex A. Adjei
    BJC Reports, 3 (1):
  • [23] PHASE I STUDY OF THE PHARMACOKINETICS AND TOLERABILITY OF EVEROLIMUS IN CHINESE PATIENTS WITH ADVANCED SOLID TUMORS
    Xu, B.
    Shen, L.
    Ye, D.
    Jappe, A.
    Cherfi, A.
    Wang, H.
    Yuan, R.
    Wu, Y.
    ANNALS OF ONCOLOGY, 2010, 21 : 178 - 178
  • [24] A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors
    Kelly, W.
    Petrylak, D.
    Blumenschein, G.
    Lassen, U.
    Jensen, P. Buhl
    DeBono, J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 127 - 127
  • [25] Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): A phase I dose-finding study
    Chiorean, E. G.
    Sweeney, C. J.
    Verschraegen, C. F.
    Lee, F. C.
    Jones, S. F.
    Rabinowitz, I.
    Tye, L.
    Bello, A.
    Chao, R.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.
    Tan, David Shao Peng
    Pang, Mei-Yan
    Yong, Wei Peng
    Soo, Ross A.
    Chee, Cheng Ean
    Thian, Yee Liang
    Gopinathan, Anil
    Wong, Andrea Li Ann
    Koe, Priscillia
    Sundar, Raghav
    Ho, Jingshan
    Friedlander, Sharon
    Landesman, Yosef
    Rashal, Tami
    McCauley, Dilara
    Shacham, Sharon
    Lee, Soo Chin
    Goh, Boon C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Phase I trial with farnesyltransferase inhibitor R115777 in patients (pts) with advanced solid tumors
    Punt, CJA
    Peters, M
    van Maanen, L
    van de Walle, B
    Bol, C
    Willems, L
    Horak, I
    Palmer, P
    Wagener, DJT
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S291 - S291
  • [28] Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
    Macarulla, Teresa
    Cervantes, Andres
    Elez, Elena
    Rodriguez-Braun, Edith
    Baselga, Jose
    Rosello, Susana
    Sala, Gemma
    Blasco, Inma
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Shinde, Vaishali
    Chakravarty, Arijit
    Bowman, Douglas
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Tabernero, Josep
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2844 - 2852
  • [29] Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.
    Eckhardt, S. G.
    Gallant, G.
    Sikic, B. I.
    Camidge, D. R.
    Burris, H. A., III
    Wakelee, H. A.
    Messersmith, W. A.
    Jones, S. F.
    Colevas, A. D.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Safety, tolerability, and pharmacokinetics (PK) of rilotumumab in Japanese patients (pts) with advanced solid tumors.
    Doi, Toshihiko
    Tang, Rui
    Zhang, Yilong
    Loh, Elwyn
    Lizambri, Richard
    Yasui, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345